New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 10, 2014
08:05 EDTSLXPSalix price target raised to $150 from $125 at Brean Capital
Brean Capital raised its price target on Salix to $150 from $125 to reflect the tax inversion benefits of its Cosmo acquisition. The firm also cited the addition of patents from Cosmo and positive TARGET 3 data for Xifaxan for use in irritable bowel syndrome and keeps its Buy rating on the stock.
News For SLXP From The Last 14 Days
Check below for free stories on SLXP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 20, 2014
17:59 EDTSLXPAllergan talks with Salix in defense tactic said to be dormant, Bloomberg says
Subscribe for More Information
17:35 EDTSLXPAllergan said to explore options outside of Salix acquisition, Bloomberg says
Subscribe for More Information
10:53 EDTSLXPAnalysts say Salix takeover would boost Allergan
Subscribe for More Information
09:46 EDTSLXPAllergan merger deal not imminent, CNBC's Faber reports
An acquisition by Allergan (AGN) is not imminent, CNBC's David Faber reports. Salix (SLXP) and Jazz Pharmaceuticals (JAZZ) are said to be potential targets of the company, Faber adds. Valeant (VRX) could announce over the next few days that it has enough votes to call for a special meeting, the reported said.
07:19 EDTSLXPPossible Allergan Salix deal could be 8% accretive in '15-'16, says Wells Fargo
After The Wall Street Journal reported that Allergan (AGN) had approached Salix (SLXP) and other companies about a potential acquisition, Wells Fargo thinks that a largely debt financed purchase of Salix could be 8% accretive for Allergan in 2015-2016, reaching 12% accretion in 2018.
07:04 EDTSLXPSalix buyout price could be near $192 per share, says William Blair
William Blair believes a combined Allergan (AGN) and Salix (SLXP) would be very attractive. The firm estimates a potential takeover price for Salix towards the high end of its $176-$192 per share range. Salix rose 16% yesterday to $160.80 after Wall Street Journal reported that Allergan approached the company and at least one other about a takeover.
August 19, 2014
17:14 EDTSLXPOn The Fly: Closing Wrap
Subscribe for More Information
16:52 EDTSLXPAllergan all-cash deal would reduce hostile bid chances, says BMO Capital
Subscribe for More Information
14:40 EDTSLXPSterne Agee says Allergan could pay up to $190 for Salix and still be accretive
Subscribe for More Information
13:28 EDTSLXPJazz moves higher after WSJ report of Salix approach by Allergan
Subscribe for More Information
13:15 EDTSLXPSalix options active after WSJ report of Allergan approach
Subscribe for More Information
13:13 EDTSLXPAllergan approached Salix, one other about takeover, WSJ reports
Subscribe for More Information
13:06 EDTSLXPSalix jumps 6% to $147.85 after WSJ report of Allergan approach
Subscribe for More Information
13:05 EDTSLXPAllergan approached Salix about takeover, WSJ reports
07:02 EDTSLXPSalix announces early termination of HSR Waiting Period for Cosmo transaction
Subscribe for More Information
August 18, 2014
17:18 EDTSLXPVisium Asset Management reports 4.9 % passive stake in Salix
Subscribe for More Information
11:41 EDTSLXPCubist rises after report sparks takeover interest speculation
Subscribe for More Information
August 14, 2014
14:17 EDTSLXPViking Global Investors reports 5.0% passive stake in Salix
Subscribe for More Information
August 11, 2014
14:05 EDTSLXPSalix announces results from TARGET 3 trial
Subscribe for More Information
07:06 EDTSLXPSalix, Progenics receive FDA PDUFA date of September 29 for Relistor sNDA
Salix Pharmaceuticals (SLXP) and Progenics Pharmaceuticals (PGNX) announced that the FDA has informed Salix that the supplemental New Drug Application for RELISTOR Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use